Answers are grounded in this paper and cite their sources.
CYP2C19*2 polymorphism is associated with increased total gliclazide concentration and reduced oral clearance. Pharmacogenetic studies are warranted on the impact of CYP2C19 polymorphisms on treatment response and hypoglycaemia.
No takes yet. Share an insight, caveat, or question.
Chow et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: